Global E-Health Forum - Hamburg 2011

11 - 13 October 2011, Hamburg, Germany.
Improving the quality of healthcare, increasing the efficiency of the systems and ensuring patient empowerment - these are the common goals worldwide when discussing the necessary transformation of the systems in order to guarantee a sustainable healthcare delivery in the future. The Global E-Health Forum - Hamburg 2011 will represent major stakeholders involved in designing personalized healthcare.

"E-Health is increasingly seen as a key enabler for this transformation," so Ljubisav Matejevic, founder and honorary chairman of the Global E-Health Forum. "And as a key enabler for the evolution process towards personalized healthcare. Healthcare that is proactive, instead of reactive, gives the patients the opportunity and the responsibility to become more involved in their own health. The ultimate goal will be to shape preventive and diagnostic care to match each person's unique characteristics."

The initiators of the Global E-Health Forum - Hamburg Chamber of Commerce, IBM and ICC - have developed this platform to discuss e-health strategies, best practices and new services/patient-centric approaches in a global context. While the main target groups consist of CEOs, CIOs and CFOs of hospitals and clinics, the comprehensive program will also attract representatives from governmental bodies, health insurance organizations, service providers, influencers from hospital and health management associations as well as representatives from universities/research institutes. Canada supports the Global E-Health Forum - Hamburg 2011 as partner country.

The first two conference days will feature speakers from all over the globe:

  • Richard C. Alvarez, President and Chief Executive Officer of Canada Health Infoway, with "Transforming Healthcare in Canada through E-Health"
  • Prof. WEN Ze Huai, (M. D.), Key Unit of Methodology in Clinical Research, Guangdong Traditional Chinese Medicine International Clinical Research Center, Research Center Guangdong Academy of Chinese Medical Sciences, with "Designing Personalized Healthcare for Integrated Medicine by Using Information Technology"
  • Dr. Eric M. Liederman, Director of Medical Informatics, The 45 Permanente Medical Group (USA), with "Balancing Privacy Protection with Patient Care"
  • Prof. Dr. Roland Eils, Division Head "Theoretical Bioinformatics", German Cancer Research Center (DKFZ) and Manuela Mueller-Gerndt, Healthcare Leader, IMT Germany, Smarter Healthcare, IBM Deutschland GmbH with "Oncology as a Key Driver for Cancer Research and Individualized Medicine"
  • Chai Chuah, National Director, National Health Board Business Unit, New Zealand Ministry of Health, with "Sustainable Personalized Healthcare - Challenges and Opportunities"

Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. During the evening reception at the U.S. Consulate General on October 11, there will be manifold opportunity of knowledge and experience exchange as well as networking. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups. The third day is dedicated to guided tours of different hospitals and clinics in Hamburg, three of them being Asklepios clinics. The Asklepios Hospital Group renewed its cooperation partnership with the Global E-Health Forum.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

AstraZeneca takes next steps towards broad and equ…

AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements ...

Johnson & Johnson announces acceleration of it…

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Calquence showed promising clinical improvement in…

Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved cl...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

New consortium EUbOPEN will provide tools to unloc…

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to bet...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Mayo finds convalescent plasma safe for diverse pa…

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findi...